DNA vaccine shown to provide long-term protection from Ebola

A synthetic DNA vaccine developed by researchers at The Wistar Institute Vaccine & Immunotherapy Center has been shown to provide complete and enduring protection from Ebola virus in preclinical studies.

Illustration of the ebola virus by FestaImage Credit: Festa / Shutterstock

According to the World Health Organization, Ebola causes a severe hemorrhagic fever that kills 50% of people.

Promising candidate vaccines have been developed in recent years, but they have been associated with potential side effects and/or may not be suitable for administration to vulnerable populations such as pregnant women, children and people with compromised immune systems.

Furthermore, the vaccines need to be improved to ensure long-term protection.

As reported in the Journal of Infectious Diseases, Wistar scientists have now designed synthetic DNA vaccines targeting surface glycoproteins on the Ebola virus.

In animal models, the vaccines were shown to be effective and demonstrated durability of the immune system, with the animals exhibiting strong immune responses one year after receiving a last dose.

This important finding supports the long-term immunogenicity of the vaccine, an area that has proved challenging previously in Ebola vaccine research.

For the study, the team optimized a shorter, dose-sparing vaccination technique and simplified administration to intradermal delivery.

The new approach resulted in fast and protective immunity to the virus and the level of antibodies generated was equal or higher than the level reported for other vaccines.

Synthetic non-viral based DNA technology allows for rapid vaccine development by delivery directly into the skin, resulting in consistent, potent and rapid immunity compared to traditional vaccine approaches."

David Weiner, Lead Researcher

Weiner says a vaccine like this could be an important new tool for protecting against Ebola and that the researchers are excited to see what further studies reveal.

The success of intradermal delivery of a low-dose regimen is very encouraging. The ultimate goal of our work is to create effective and safe vaccines that are optimized for field use in at-risk areas.”

Ami Patel, Scientist

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, October 11). DNA vaccine shown to provide long-term protection from Ebola. News-Medical. Retrieved on May 21, 2019 from https://www.news-medical.net/news/20181011/DNA-vaccine-shown-to-provide-long-term-protection-from-Ebola.aspx.

  • MLA

    Robertson, Sally. "DNA vaccine shown to provide long-term protection from Ebola". News-Medical. 21 May 2019. <https://www.news-medical.net/news/20181011/DNA-vaccine-shown-to-provide-long-term-protection-from-Ebola.aspx>.

  • Chicago

    Robertson, Sally. "DNA vaccine shown to provide long-term protection from Ebola". News-Medical. https://www.news-medical.net/news/20181011/DNA-vaccine-shown-to-provide-long-term-protection-from-Ebola.aspx. (accessed May 21, 2019).

  • Harvard

    Robertson, Sally. 2018. DNA vaccine shown to provide long-term protection from Ebola. News-Medical, viewed 21 May 2019, https://www.news-medical.net/news/20181011/DNA-vaccine-shown-to-provide-long-term-protection-from-Ebola.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post